Surgery: Future directions in multimodality therapy for NSCLC

Nature Reviews Clinical Oncology

Volumn 7, Issue 1, 2010, Pages 10-12

  Tsao, Anne S ^a   Roth, Jack A ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDICAL DECISION MAKING; MOLECULAR MODEL; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SHORT SURVEY; SURGICAL MORTALITY; TREATMENT OUTCOME;

EID: 76849085262     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.174     Document Type: Short Survey

References (10)

1. Albain, K. s. et al. Radiotherapy plus chemotherapy with or without surgical resection for stage iii non-small-cell lung cancer: a phase iii randomised controlled trial. Lancet 374, 379-386 (2009).
2. van Meerbeeck, J. P. et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage iiiA-n2 non-small-cell lung cancer. J. Natl Cancer Inst. 99, 442-450 (2007).
3. stupp, R. et al. neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage iiiB non-small-cell lung cancer: a multicentre phase ii trial. Lancet Oncol. 10, 785-793 (2009).
4. Albain, K. s. et al. Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages iiiA (n2) and iiiB non-small-cell lung cancer: mature results of southwest Oncology Group phase ii study 8805. J. Clin. Oncol. 13, 1880-1892 (1995).
5. Thomas, M. et al. effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage iii non-small-cell lung cancer. Lancet Oncol. 9, 636-648 (2008).
6. Fukuoka, M. et al. Biomarker analysis from a phase iii, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (iPAss) [abstract]. J. Clin. Oncol. 27, 8006 (2009).
7. Kelly, K. et al. Phase iii trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage iii non-small-cell lung cancer: swOG s0023. J. Clin. Oncol. 26, 2450-2456 (2008).
8. Koivunen, J. P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008).
9. Karp, D. et al. High activity of the anti-iGFR antibody CP-751871 in combination with paclitaxel and carboplatin in squamous nsCLC [abstract]. J. Clin. Oncol. 26, 8015 (2008).
10. Potti, A. et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355, 570-580 (2006). (Pubitemid 44200650)